STOCK TITAN
  1. Home
  2. Sec-filings
  3. NAUT
  4. [8-K] Nautilus Biotechnology, Inc. Reports Material Event

Nautilus Biotechnology (NASDAQ: NAUT) shifts roadmap after Q2 2026 results

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Nautilus Biotechnology reported second quarter 2026 results, recognizing its first revenue of $0.2 million, primarily grant income from The Michael J. Fox Foundation and service revenue from its Iterative Mapping Early Access Program. Operating expenses were $15.9 million, down from $17.1 million a year earlier, resulting in a net loss of $14.5 million versus $15.0 million. Cash, cash equivalents and investments totaled $129.2 million as of June 30, 2026.

The company is reallocating resources to accelerate proteoform applications in response to strong customer interest. The Voyager platform is expected to open for pre-orders in early 2027, with instrument shipments beginning mid‑2027 alongside Tau and AKT1 proteoform assay kits and additional oncology proteoform assays through late 2027. Testing showed current assay configuration changes do not support a 2027 broadscale consumable kit at target specifications, and Nautilus plans to update the commercial timeline after further development.

Positive

  • Recognized $0.2 million in revenue in Q2 2026, the company’s first reported revenue, reflecting initial commercialization through grant funding and Early Access service income.
  • Reduced Q2 2026 operating expenses to $15.9 million, a 7% decrease from $17.1 million in the prior-year quarter, slightly narrowing net loss.
  • Maintained $129.2 million in cash, cash equivalents and investments as of June 30, 2026, providing substantial resources to continue developing the Voyager platform and proteoform assays.

Negative

  • Reported a Q2 2026 net loss of $14.5 million, with net loss for the first six months of 2026 totaling $29.2 million.
  • Concluded that current assay configuration changes do not sufficiently improve probe performance to support a 2027 general availability broadscale consumable kit at target specifications, delaying broadscale commercialization beyond the earlier 2027 objective.

Filing Explained

This July 28 Form 8-K furnishes Nautilus’s second-quarter results under Item 2.02; through June 30, it reported net cash used in operating activities while cash, cash equivalents, and investments were $129.2 million, showing continued operating cash consumption alongside reported liquidity.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 Revenue $0.2 million Total revenue for the quarter ended June 30, 2026
Q2 2026 Operating Expenses $15.9 million Operating expenses for the quarter ended June 30, 2026, down from $17.1 million a year earlier
Q2 2026 Net Loss $14.5 million Net loss for the quarter ended June 30, 2026, versus $15.0 million in the prior-year quarter
Cash, Cash Equivalents and Investments $129.2 million Combined balance as of June 30, 2026
Net Cash Used in Operating Activities $26,826 (in thousands) Net cash used in operating activities for the six months ended June 30, 2026 (in thousands)
single-molecule proteome analysis platform technical
"a company pioneering a single-molecule proteome analysis platform, today reported financial results"
proteoform medical
"customer enthusiasm for the proteoform approach and the unique insight it can deliver"
A proteoform is a specific version of a protein that results when the same gene produces slightly different end products through small sequence differences or chemical changes after the protein is made. For investors, proteoforms matter because these subtle differences can change how a drug works, how reliably a diagnostic test detects disease, and how regulators view safety and effectiveness—similar to how different trims of the same car model can affect performance, price, and customer choice.
Iterative Mapping Early Access Program technical
"we launched our Iterative Mapping Early Access program, a services-based program designed"
operating lease right-of-use assets financial
"Operating lease right-of-use assets | 25,619 | | | 27,773"
An operating lease right-of-use (ROU) asset is an accounting entry that shows the value of a leased item you have the legal right to use—like a building, vehicle, or equipment—recorded on a company’s balance sheet along with the corresponding lease obligation. Investors care because it adds to reported assets and liabilities, changing measures like leverage and return on assets much like bringing a long-term rental onto the company’s financial snapshot, which can affect credit terms and valuation.
stock-based compensation financial
"The decrease in operating expenses is attributable to lower salaries and related benefits, stock-based compensation expense"
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
Revenue $0.2 million Up from $0 in the quarter ended June 30, 2025.
Operating expenses $15.9 million Down from $17.1 million in the quarter ended June 30, 2025.
Net loss $14.5 million Compared with $15.0 million in the quarter ended June 30, 2025.
Cash, cash equivalents and investments $129.2 million Balance as of June 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Nautilus Biotechnology’s (NAUT) revenues in Q2 2026?
Nautilus reported $0.2 million in revenue for Q2 2026, its first recognized revenue. This consisted primarily of grant revenue from The Michael J. Fox Foundation and initial service revenue from its Iterative Mapping Early Access Program.

How large was Nautilus Biotechnology’s (NAUT) Q2 2026 net loss?
Nautilus recorded a net loss of $14.5 million in Q2 2026, compared with a $15.0 million net loss in the same quarter of 2025. For the first six months of 2026, net loss totaled $29.2 million.

What cash and investments did NAUT have as of June 30, 2026?
As of June 30, 2026, Nautilus held $129.2 million in cash, cash equivalents and investments. This liquidity position supports ongoing R&D on the Voyager platform, proteoform assays, and related commercial readiness activities.

How is Nautilus Biotechnology (NAUT) changing its product roadmap?
Nautilus is reallocating resources to accelerate its proteoform applications, citing strong customer enthusiasm. The company is emphasizing Iterative Mapping services, Tau and AKT1 proteoform assays, and additional oncology proteoform assays, while adjusting timelines for its broadscale consumable kit.

When will Nautilus Biotechnology’s (NAUT) Voyager platform launch?
The Voyager platform is expected to open for pre-orders in early 2027, with instrument shipments beginning in mid‑2027. Launch timing is coordinated with general availability of proteoform assay consumable kits, including Tau and AKT1 assays.

What is the status of Nautilus Biotechnology’s (NAUT) broadscale consumable kit?
Testing showed current assay configuration changes do not support 2027 general availability of a broadscale consumable kit at target specifications. Nautilus has identified improvement areas and plans to provide an updated commercial timeline after further development work.
0001808805FALSE00018088052026-07-282026-07-28



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2026
NAUTILUS BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
001-39434
(Commission File Number)
98-1541723
(I.R.S. Employer
Identification No.)
2701 Eastlake Avenue East
Seattle, Washington
(Address of principal executive offices)
98102
(Zip code)
(206) 333-2001
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NAUT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 2.02.    Results of Operations and Financial Condition.
On July 28, 2026, Nautilus Biotechnology, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit
Number
Description
99.1
Press Release dated July 28, 2026.
104Cover page Interactive Data File (embedded with the Inline XBRL document)
2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 28, 2026
NAUTILUS BIOTECHNOLOGY, INC.
By:/s/ Sujal Patel
Name:Sujal Patel
Title:Chief Executive Officer

Exhibit 99.1
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Business Highlights
•Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J. Fox Foundation supporting our alpha-synuclein proteoform assay development, together with revenue from our first Iterative Mapping Early Access Program customer.
•Grew our commercial organization to three team members, including our previously announced VP of Global Sales, driving engagement with prospective Iterative Mapping Early Access Program customers ahead of the Voyager™ Platform commercial launch.
•We have selected and are advancing our first oncology proteoform, AKT1, with expected Early Access availability in late 2026.

Programs & Roadmap Update

In Q1, we launched our Iterative Mapping Early Access program, a services-based program designed to bring Iterative Mapping applications to customers ahead of general availability of consumable kits, with our Tau Proteoforms Assay as the first application made available. Since launch, we have seen strong and growing customer enthusiasm for the proteoform approach and the unique insight it can deliver, including numerous additional customer-requested proteoform targets, representing what we believe to be a significant commercial opportunity. Given the potential scale of this opportunity and the technical performance to date, we are significantly shifting resources across the company and putting a new roadmap in place to accelerate our proteoform applications. Our new realigned roadmap includes:

Voyager™ Platform
•Launch expected in early 2027 for pre-orders and anticipated instrument shipment beginning in mid 2027, timed with the Proteoforms Assay consumable kits listed below.
Proteoform Portfolio
•Tau Proteoforms Assay: Continued availability through the Iterative Mapping Early Access Program with general availability of consumable kits in mid 2027.
•AKT1 Proteoforms Assay: Expected to enter the Iterative Mapping Early Access Program in late 2026, with general availability of consumable kits expected in mid 2027.
•Second oncology proteoforms assay with expected general availability of consumable kits in mid 2027
•Third oncology proteoforms assay and continued expansion of our proteoform pipeline with general availability of additional consumable kits in late 2027.
•We plan to concurrently develop expanded proteoform portfolio capabilities, such as lower sample input, additional sample types, and increased proteoform depth.
Broadscale Portfolio
•In Q2, we completed testing and determined that our assay configuration changes do not sufficiently improve our probe candidate performance to support a 2027 general availability of a broadscale consumable kit at our target specifications.
•We have identified key improvement areas and begun the necessary development work required to advance broadscale performance.
•We plan to report back on a commercial timeline for the Broadscale Assay at a future date.

“The second quarter reinforced our ever-increasing conviction that proteoforms deliver critical biological resolution that Nautilus is uniquely positioned to deliver,” said Sujal Patel, CEO of Nautilus Biotechnology. “Customer enthusiasm for our proteoform applications has been remarkable, and we are prioritizing this market-driven feedback in our updated roadmap. We are funding this shift through reallocation rather than incremental spend, so accelerating our proteoform development does not impact our broader financial assumptions. I believe this realignment puts Nautilus on a more direct and, ultimately, faster path to becoming a commercial company.”
1

Second Quarter 2026 Financial Results
Revenue was $0.2 million for the second quarter of 2026, primarily driven by grant revenue from the commencement of the Company’s activities related to the grant awarded from The Michael J. Fox Foundation during the period, and service revenue for the first sales of services under the Iterative Mapping Early Access Program.
Operating expenses were $15.9 million for the second quarter of 2026, a $1.2 million or 7% decrease compared to $17.1 million for the corresponding prior year period. The decrease in operating expenses is attributable to lower salaries and related benefits, stock-based compensation expense, and facilities costs.
Net loss was $14.5 million for the second quarter of 2026, as compared to the net loss of $15.0 million for the corresponding prior year period.

Cash, cash equivalents, and investments were $129.2 million as of June 30, 2026.
Webcast and Conference Call Information
Nautilus will host a conference call to discuss the second quarter 2026 financial results, business developments and outlook before market open on Tuesday, July 28, 2026, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations regarding operating expenses and cash runway, including any impact thereon from our reallocation of resources; expectations with respect to any revenue timing or projections; expectations with respect to the development required for and the timing of the launch of the Nautilus VoyagerTM platform, our proteoform applications roadmap and full commercial availability of our proteoform and/or broadscale products and/or services; the functionality and performance of the Nautilus Voyager platform, its potential impact on providing proteome or proteoform access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery; expectations regarding platform specifications required by potential customers and partners and the timeline for adoption of the Nautilus Voyager platform by researchers; and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: the Nautilus Voyager product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience
2

material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended June 30, 2026 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information

Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
3
Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
As of June 30, 2026 and December 31, 2025 (Unaudited)

(in thousands)
June 30, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$13,166 $12,388 
Short-term investments70,865 91,018 
Prepaid expenses and other current assets3,595 2,557 
Total current assets87,626 105,963 
Property and equipment, net3,999 3,457 
Operating lease right-of-use assets25,619 27,773 
Long-term investments45,155 52,739 
Other long-term assets1,177 1,180 
Total assets$163,576 $191,112 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$1,095 $943 
Accrued expenses and other liabilities3,553 3,177 
Current portion of operating lease liabilities3,991 3,832 
Total current liabilities8,639 7,952 
Operating lease liabilities, net of current portion23,825 26,187 
Total liabilities32,464 34,139 
Stockholders’ equity:
Preferred stock— — 
Common stock13 13 
Additional paid-in capital492,616 488,737 
Accumulated other comprehensive income (loss)(331)243 
Accumulated deficit(361,186)(332,020)
Total stockholders’ equity131,112 156,973 
Total liabilities and stockholders’ equity$163,576 $191,112 

4
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
Three and Six Months Ended June 30, 2026 and 2025 (Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
(in thousands, except share and per share data)2026202520262025
Revenue:
Grant revenue$180 $— $180 $— 
Service revenue10 — 10 — 
Total revenue190 — 190 — 
Cost of revenue:
Cost of service revenue15 — 15 — 
Total cost of revenue15 — 15 — 
Operating expenses:
Research and development9,613 10,394 19,320 21,930 
Selling, general and administrative6,325 6,703 12,742 14,011 
Total operating expenses15,938 17,097 32,062 35,941 
Other income (expense):
Interest income1,307 2,080 2,749 4,311 
Other expense(13)(16)(28)(16)
Total other income$1,294 $2,064 $2,721 $4,295 
Net loss$(14,469)$(15,033)$(29,166)$(31,646)
Net loss per share attributable to common stockholders, basic and diluted$(0.11)$(0.12)$(0.23)$(0.25)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted127,135,738 126,204,632 126,886,646 126,174,603 

5
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
Six Months Ended June 30, 2026 and 2025 (Unaudited)

Six Months Ended June 30,
(in thousands)20262025
Cash flows from operating activities
Net loss$(29,166)$(31,646)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation2,520 3,877 
Amortization of operating lease right-of-use assets2,154 2,336 
Depreciation606 922 
Amortization (accretion) of premiums (discounts) on securities, net(56)(980)
Changes in operating assets and liabilities:
Prepaid expenses and other assets(953)160 
Accounts payable(104)(51)
Accrued expenses and other liabilities376 390 
Operating lease liabilities(2,203)(2,295)
Net cash used in operating activities(26,826)(27,287)
Cash flows from investing activities
Proceeds from maturities of securities55,715 45,878 
Purchases of securities(28,496)(11,278)
Purchases of property and equipment(964)(615)
Net cash provided by investing activities26,255 33,985 
Cash flows from financing activities
Proceeds from exercise of stock options1,207 26 
Proceeds from issuance of common stock under employee stock purchase plan142 87 
Net cash provided by financing activities1,349 113 
Net increase in cash, cash equivalents and restricted cash778 6,811 
Cash, cash equivalents and restricted cash at beginning of period13,390 28,648 
Cash, cash equivalents and restricted cash at end of period$14,168 $35,459 

6

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents